 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C28H31N3O6 |
| Molar mass | 505.571 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Benidipine is a dihydropyridine calcium channel blocker for the treatment ofhigh blood pressure (hypertension). It is a tripleL-,T-, andN-typecalcium channel blocker. It is reno- and cardioprotective.
It was patented in 1981 and approved for medical use in 1991.[1]
Benidipine is dosed as 2–8 mg once daily.[2]
Benidipine is acalcium channel blocker.
Benidipine has additionally been found to act as anantagonist of themineralocorticoid receptor, or as anantimineralocorticoid.[3]
Other names include Benidipinum or benidipine hydrochloride.
Benidipine is sold as Coniel by Kyowa Hakko Kogyo.
Benidipine is initially licensed for use in Japan and selectedSoutheast Asian countries and later in Turkey, where it is sold as 4 mg tablets.